The Trump administration canceled a Biden-era plan on Friday that would have made Ozempic and other weight-loss drugs ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

"Ozempic is very easy to get nowadays, and people all over are getting their hands on it. But don't do it. I messed up.

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

The deal comes as Novo Nordisk moves to become the leader ... The Danish maker of Ozempic has dominated the space with its Wegovy, but is facing competition from Eli Lilly's Zepbound (tirzepatide).

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

GDANSK/LONDON (Reuters) - Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales ...

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...